Watchdog finds lax U.S. oversight of doctor conflicts

WASHINGTON (Reuters) - U.S. regulators need to improve lax oversight of the financial conflicts of doctors who test medicines before they are approved for sale, a government watchdog report said on Monday.

The Food and Drug Administration lacks a complete list of doctors conducting research on new medicines and cannot determine which companies have submitted financial information for all doctors working on studies, according to a report by the Department of Health and Human Services inspector general.

Investigators examined materials submitted for 118 marketing applications of medicines or medical devices approved in fiscal 2007.

Forty-two percent of the applications were missing financial information, the report said. The FDA did not document a review of any financial data for 31 percent of the applications.

The report urged the agency to take several steps to make sure companies submit complete financial information for doctors and that agency reviewers check the submissions.

It also said the FDA should require companies to submit financial information for doctors before clinical trials on people begin.

The FDA objected to that idea, saying it would add another layer of review that would not necessarily help patients.

“This recommendation could have the unintended effect of adding to the complexity and cost of the clinical trial enterprise with no commensurate gain in the protection of human subjects or the quality of the data,” FDA spokeswoman Karen Riley said.

The agency agreed with the report’s other recommendations, Riley said.


Related Posts:

WASHINGTON (Reuters) - U.S. regulators are asking drugmakers to submit more details about their supply chains under a pilot program announced on Wednesday to help protect patients from fake or tainted medicines from overseas. Companies that voluntarily provide the information can get the products through U.S. border entry points more quickly, Food and Drug Administration officials

Full Post: U.S. seeks details of supply chains for foreign drugs

WASHINGTON (Reuters) - U.S. regulators issued guidelines on Monday that make it easier for drug companies and medical device makers to advise doctors about unapproved uses of their products. The Food and Drug Administration finalized a proposal issued in February 2008 that lets companies distribute medical journal articles describing unapproved uses. By law, manufacturers are prohibited from

Full Post: FDA lets drugmakers advise doctors on unapproved uses

By Lisa Richwine WASHINGTON (Reuters) - U.S. regulators should make sure high-risk medical devices undergo the agency’s toughest review process before they are allowed on the market, a congressional watchdog report said on Thursday. The Food and Drug Administration oversees devices ranging from simple bandages and tongue depressors to the most complex such as pacemakers and heart-valve

Full Post: GAO urges tougher review of some medical devices

NEW YORK (Reuters) - U.S. health regulators want longer-term data on the use of Merck & Co’s Gardasil cervical cancer vaccine in an older group of women before they will approve the vaccine for those women, the drugmaker said on Friday. The U.S. Food and Drug Administration has issued a second complete response letter to Merck

Full Post: More data sought for Merck’s Gardasil in older women

CHICAGO (Reuters) - Internal company documents suggest Johnson & Johnson, maker of the antipsychotic drug Risperdal, agreed to fund a child psychiatry research center at Massachusetts General Hospital to generate data to support use of the drug in children, the Wall Street Journal reported on Monday. The drug, known generically as risperidone, recently came under fire

Full Post: J&J helped plan child research institute: report

Site Navigation

Most Read